Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991210 · ClinicalTrials.gov registry record · Phase 2
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT01991210 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 95 participants.
The verdict
NCT01991210, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram (mg/kg) intravenously (IV) every 3 weeks or PLD 40 milligrams per meter-squared (mg/m\^2) IV every 4 weeks.
Interventions
- DRUG PLD
- DRUG DNIB0600A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-02-06 |
| Est. Completion | 2016-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01991210
The ClinicalTrials.gov registry entry for NCT01991210 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLD is the first listed.
NCT01991210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01991210 about?
NCT01991210 is a clinical study titled "A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)". This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram ...
What is the current status of trial NCT01991210?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2014-02-06. Estimated completion is 2016-08-17.
What interventions are being tested in trial NCT01991210?
The interventions under investigation include: PLD (DRUG), DNIB0600A (DRUG).
Who is sponsoring clinical trial NCT01991210?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.